Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pak J Med Sci. 2014 Jan;30(1):7-11. doi: 10.12669/pjms.301.3908.

Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus with chronic heart failure.

Author information

  • 1Xuyang Liu, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
  • 2Chengfu Zhong, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
  • 3Pengtai Zhao, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
  • 4Zhihua Zhang, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
  • 5Ning Jia, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
  • 6Sheng'ou Su, Department of Endocrinology, Second Hospital of Hebei Medical University, Shijiazhuang 050000, P. R. China.
  • 7Benliang Zou, Department of Endocrinology, Xiyuan Hospital CACMS, Beijing 010000, P. R. China.
  • 8Yuming Song, Department of Traditional Chinese Medicine, First Center Hospital of Baoding, Baoding 071000, P. R. China.

Abstract

OBJECTIVE:

To explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure (CHF) patients complicated with diabetes mellitus (DM). Method s : One hundred and fifty-four elderly patients were randomly divided into an observation group and a control group (n=77), which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. The New York Heart Association (NYHA) classification, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), 6-min walking distance and medication safety of the two groups were compared.

RESULTS:

Compared with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF and 6-minutes walking distance of both groups were significantly improved (P<0.05), with significantly better results in the observation group than those in the control group after treatment (P<0.05). In the 6 months of follow-up, the incidence of cardiac events in the observation group (3.90%) was significantly lower than that of the control group (14.29%) (P<0.05). The levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences (P>0.05).

CONCLUSION:

Treating CHF patients complicated with DM with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance.

KEYWORDS:

Chronic heart failure; Diabetes mellitus; Metoprolol; Safety; Therapeutic effect

PMID:
24639821
[PubMed]
PMCID:
PMC3955532
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk